Atipamezole Hydrochloride

Alpha-2 adrenergic antagonist Imidazole derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IM 0.05-0.1 mg/kg (5 times the medetomidine dose on a mg basis) or 0.1-0.2 mg/kg for dexmedetomidine reversal Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer at the same site as the alpha-2 agonist if possible. Dose should be adjusted based on the dose of alpha-2 agonist used.
Cat IM 0.05-0.1 mg/kg (5 times the medetomidine dose) or 0.1-0.2 mg/kg for dexmedetomidine reversal Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer at the same site as the alpha-2 agonist if possible.
Horse IV 0.02-0.04 mg/kg (or 4-8 times the detomidine dose on a mg basis) Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer slowly IV. Monitor for signs of arousal and cardiovascular changes.
Cattle IV 0.02-0.04 mg/kg (or 4-8 times the xylazine dose on a mg basis) Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer slowly IV. Monitor for signs of arousal and cardiovascular changes.
Small Ruminants (Sheep, Goats) IV 0.02-0.04 mg/kg (or 4-8 times the xylazine dose on a mg basis) Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer slowly IV. Monitor for signs of arousal and cardiovascular changes.
Rabbit IM 0.1-0.2 mg/kg (or 5 times the medetomidine dose) Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Administer at the same site as the alpha-2 agonist if possible.
Bird (e.g., Psittacines) IM 0.1-0.2 mg/kg (or 5 times the medetomidine dose) Single dose; may repeat once if needed after 10-15 minutes Duration: Single administration
Notes: Use with caution; monitor for respiratory depression.

Clinical Indications & Species Uses

General Indications
  • Reversal of alpha-2 adrenergic agonist-induced sedation, analgesia, and muscle relaxation in veterinary medicine
Dog (Canine)
  • Reversal of sedation and analgesia induced by medetomidine or dexmedetomidine
  • Reversal of xylazine sedation
  • Reversal of alpha-2 agonist effects in emergency situations
Cat (Feline)
  • Reversal of sedation and analgesia induced by medetomidine or dexmedetomidine
  • Reversal of xylazine sedation
Horse (Equine)
  • Reversal of sedation and analgesia induced by detomidine or romifidine
  • Reversal of xylazine sedation
Cattle (Bovine)
  • Reversal of sedation and analgesia induced by xylazine or detomidine
Small Ruminants (Sheep / Goat)
  • Reversal of sedation and analgesia induced by xylazine or detomidine
Rabbit & Small Mammals
  • Reversal of sedation and analgesia induced by medetomidine or dexmedetomidine
Avian & Poultry
  • Reversal of sedation and analgesia induced by medetomidine or dexmedetomidine (in some avian species)
Exotic & Other Species
  • Reversal of alpha-2 agonist sedation in various exotic species (e.g., reptiles, small mammals) when used off-label

Pharmacology & Mechanism of Action

Drug Class: Alpha-2 adrenergic antagonist | Pharmacological Group: Imidazole derivative

Mechanism of Action: Atipamezole is a potent, selective, and reversible antagonist of alpha-2 adrenergic receptors. It competitively blocks the effects of alpha-2 agonists such as medetomidine, dexmedetomidine, and xylazine at central and peripheral receptors. By displacing these agonists, atipamezole rapidly reverses sedation, analgesia, and muscle relaxation induced by alpha-2 agonists. It has negligible activity at alpha-1 receptors and other receptor types, making it highly specific for alpha-2 reversal.

Pharmacodynamics: Atipamezole antagonizes alpha-2 adrenergic receptors, leading to increased central sympathetic outflow and norepinephrine release. This results in reversal of sedation, restoration of consciousness, and normalization of cardiovascular parameters (heart rate, blood pressure) that were depressed by alpha-2 agonists. The drug also reverses the gastrointestinal effects (e.g., vomiting) and respiratory depression caused by alpha-2 agonists. Its onset of action is rapid, typically within minutes after injection.

⚡ Pharmacokinetics Summary

Absorption: After intramuscular (IM) or subcutaneous (SC) administration, atipamezole is rapidly absorbed, with peak plasma concentrations occurring within 10-15 minutes. Oral absorption is poor and not used clinically.
Distribution: Atipamezole is widely distributed throughout the body, with a volume of distribution of approximately 1-2 L/kg in dogs. It crosses the blood-brain barrier to exert its central effects. Protein binding is moderate, around 40-50%.
Metabolism: Atipamezole is extensively metabolized in the liver, primarily by hydroxylation and conjugation. The metabolites are pharmacologically inactive.
Excretion: Metabolites are excreted primarily in the urine (about 60-80%) and feces (20-40%). The elimination half-life is approximately 1-2 hours in dogs and cats, but the clinical duration of action is shorter due to rapid receptor dissociation.
Half-Life: Dogs: ~1-2 hours; Cats: ~1-2 hours; Horses: ~1-1.5 hours
Bioavailability: IM/SC: ~100% (rapid absorption); Oral: poor (not used)
Protein Binding: Approximately 40-50%

Available Formulations & Strengths

Injectable Solution 5 mg/mL (as hydrochloride) (IM, SC, IV)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to atipamezole or any component of the formulation
  • Do not use in animals with severe cardiovascular disease, particularly those with pre-existing arrhythmias or hypotension
  • Do not use in animals with hepatic or renal insufficiency unless the benefits outweigh the risks
  • Do not use in animals that are severely debilitated or in shock
  • Do not use in animals that have been administered alpha-2 agonists for purposes other than sedation (e.g., as an emetic) without careful consideration
Warnings & Clinical Precautions:
  • Use with caution in animals with a history of seizures or epilepsy, as reversal may precipitate seizures in predisposed animals
  • Monitor cardiovascular parameters (heart rate, blood pressure) closely after administration, especially in animals with pre-existing cardiac disease
  • In horses, rapid IV administration may cause transient hypotension or hypertension; administer slowly
  • In food animals, observe withdrawal times before slaughter or milk production
  • Do not use in pregnant animals unless the benefits clearly outweigh the risks, as safety has not been established
  • Keep out of reach of children; avoid self-injection, as atipamezole can cause adverse effects in humans
  • Use with caution in animals that are very young or very old

Adverse Effects & Reactions

Common:

  • Vomiting
  • Diarrhea
  • Hypersalivation
  • Tremors
  • Excitement or agitation
  • Tachycardia
  • Hypotension or hypertension

Serious / Severe:

  • Cardiac arrhythmias
  • Pulmonary edema (rare)
  • Seizures (in predisposed animals)
  • Respiratory arrest (overdose)

Rare:

  • Allergic reactions (urticaria, anaphylaxis)
  • Hepatic enzyme elevations
  • Renal impairment

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other alpha-2 agonists (e.g., medetomidine, dexmedetomidine, xylazine, detomidine) Atipamezole antagonizes the effects of these drugs, leading to rapid reversal of sedation and analgesia. Concurrent use may result in arousal and potential stress. High
Tricyclic antidepressants (e.g., amitriptyline) May potentiate the cardiovascular effects of atipamezole (e.g., tachycardia, arrhythmias). Use with caution. Moderate
MAO inhibitors (e.g., selegiline) May increase the risk of hypertensive crisis due to increased norepinephrine release. Avoid concurrent use. High
Sympathomimetic agents (e.g., epinephrine, dopamine) Additive cardiovascular effects, leading to severe hypertension and tachycardia. Use with extreme caution. High
Beta-blockers (e.g., propranolol) May cause unopposed alpha-adrenergic stimulation, leading to hypertension and reflex bradycardia. Use with caution. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Tachycardia
  • Hypertension
  • Agitation
  • Tremors
  • Seizures
  • Vomiting
  • Hyperthermia
  • Respiratory distress

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Administer fluids to maintain blood pressure and perfusion. Use benzodiazepines (e.g., diazepam) to control seizures. Monitor cardiac function and treat arrhythmias as needed. In severe cases, consider administration of alpha-2 agonists (e.g., medetomidine) to counteract the effects, but this should be done with extreme caution and under veterinary supervision.

Food Animal Withdrawal Times

🥩 Meat: 3 days🥛 Milk: 2 days

Withdrawal times may vary by country and formulation. Always consult local regulations. In the US, atipamezole is not approved for food animals, but extra-label use requires extended withdrawal periods (e.g., 5 days meat, 3 days milk) as per FARAD guidelines.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F)

Handling & Special Conditions: Protect from freezing. Keep container tightly closed. Store in a dry place.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs and cats (e.g., Antisedan®). Not approved for food animals, but may be used extra-label.

Extra-Label (Off-Label) Use: In the US, atipamezole is approved for use in dogs and cats. Extra-label use in other species is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) provided there is a valid veterinarian-client-patient relationship, and appropriate withdrawal times are observed for food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Atipamezole is the drug of choice for reversal of alpha-2 agonist sedation in veterinary practice. It is highly specific and has a rapid onset of action. The dose should be calculated based on the dose of alpha-2 agonist administered, typically 5 times the medetomidine dose (on a mg basis) or 0.1 mg/kg for dogs and cats. For horses, the dose is typically 0.02-0.04 mg/kg IV. It is important to monitor animals closely after reversal, as they may become agitated or excited. In cases of accidental human exposure, seek medical attention immediately. Always follow label instructions and local regulations regarding withdrawal times for food animals.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)